FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Last week, the FDA approved the use of the drug olaparib (Lynparza), sold by AstraZeneca and Merck, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The new rules will allow the companies that make these drugs to sell them directly to consumers, rather than through wholesalers or distributors.
FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. The new rules will allow the companies that make these drugs to sell them directly to consumers, rather than through wholesalers or distributors.